Plasminogen activator inhibitor-1

• OMIM: 173 360
• UniProt: P05121

Plasminogen activator inhibitors (or Plasminogenaktivatorinhibitoren PAI ) refers to proteins in the blood, which are involved in blood clotting. They act as an inhibitor (inhibitor ) of the body's dissolution of a blood clot ( fibrinolysis ). It currently distinguishes four types of plasminogen activator inhibitors, with the Type 1 will be the main importance.

The plasminogen activator inhibitor type 1 ( PAI-1) is the most important inhibitor of the tissue-specific plasminogen activator (English tissue plasminogen activator, t -PA) and urokinase, both of which convert inactive plasminogen into plasmin. The role of plasmin is, in turn, degrade the fibrin who breastfeed as coagulation products, the blood flow to fibrin and fibrinogen. Plasmin is thus an opponent of thrombin, which causes the rapid hemostasis by forming a thrombus. PAI -1 is one of the serpins. A -induced mutation at the gene SERPINE1 ( rare ) hereditary PAI -1 deficiency is well documented.

Plasminogen activator inhibitor type 1 endothelial cells, megakaryocytes, as well as in adipocytes of visceral fat, depending on its state of charge, were synthesized. 80 % of PAI -1 activity of the blood are present in the platelets. When primary closure of a vessel wall defect secrete the activated platelet PAI -1, thereby preventing premature lysis of fibrin in the wound area.

In obesity with increase of visceral fat and the presence of diabetes mellitus type 2 or a metabolic syndrome, there is an increase of Sezer tioning of PAI -1 and thus to increase the risk of peripheral clot formation with the possibility of embolism, as well as a cardiac or cerebral infarction.

Aleplasinin is a selective inhibitor of PAI-1.